Gujarat: Corona Remedies posts 17% revenue growth, PAT up 33% in FY26

Ahmedabad: Corona Remedies Limited posted a 33% growth in its profit after tax (PAT) for FY 2026 which stood at Rs 199 crore, the company , which is headquartered in Ahmedabad, announced in a stock exchange filing. The company also posted a 17.3% rise in its annual revenues during the fiscal year which stood at Rs 1,403 crore.

The company attributes the growth to brand-building initiatives coupled with operational efficiencies and portfolio expansion.

During the year, it acquired Wokadine, marking its entry into the Rs 648-crore povidone-iodine market, funded through internal accruals. Corona Remedies also relaunched key brands in women’s health and cardiovascular therapies and set up a dedicated infertility segment team.

The pharma company said Q4FY26 revenue rose 20.2% to Rs 353 crore.

Nirav Mehta, MD and CEO, said, “The company’s focus on brand building, specialty segments like biosimilars and infertility and portfolio expansion through acquisitions continues to strengthen our competitive positioning.”